# US 2026/0060934 A1 · Pharmaceutical formulations of bictegravir and lenacapavir

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060934 A1
- Document ID: US20260060934A1
- Status: Published application
- Kind: A1
- Application number: 19/382,753
- Filed: 2025-11-07
- Published: 2026-03-05
- Earliest claimed: 2023-08-15
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Priyanka Arora; Julie A. Fogarty; Marina A. Clampffer
- Web page: https://patentgrep.com/patent/US20260060934A1

## CPC

- A61K 9/2086: {Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat (active cores with a complete drug-free outer coat A61K9/28)}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2031: {obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61P 31/18: for HIV
- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure provides a solid oral dosage form comprising bictegravir or a pharmaceutically acceptable salt thereof, and lenacapavir or a pharmaceutically acceptable salt thereof.

## Claims

### Claim at position 1

1-18. (canceled)

### Claim 19

A tablet comprising bictegravir or a pharmaceutically acceptable salt thereof and lenacapavir or a pharmaceutically acceptable salt thereof, wherein the amount of bictegravir or pharmaceutically acceptable salt thereof corresponds to about 75 mg bictegravir free acid, and wherein the amount of lenacapavir or pharmaceutically acceptable salt thereof corresponds to about 50 mg lenacapavir free acid.

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 19)

The tablet according to claim 19, wherein the tablet is a monolayer tablet.

### Claim at position 6

23-25. (canceled)

### Claim 26 (depends on 19)

The tablet according to claim 19, wherein the bictegravir or pharmaceutically acceptable salt thereof is bictegravir sodium and the lenacapavir or pharmaceutically acceptable salt thereof is lenacapavir sodium.

### Claim 27 (depends on 19)

The tablet according to claim 19, wherein the tablet further comprises at least one excipient selected from: copovidone, poloxamer, mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

### Claim 28 (depends on 27)

The tablet according to claim 27, wherein the tablet comprises copovidone, poloxamer, mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

### Claim 29 (depends on 28)

The tablet according to claim 28, wherein the tablet comprises about 5-50 mg copovidone, about 0.5-10 mg poloxamer, about 50-200 mg mannitol, about 50-250 mg microcrystalline cellulose, about 25-50 mg croscarmellose sodium and about 1-10 mg magnesium stearate.

### Claim 30 (depends on 29)

The tablet according to claim 29, wherein the tablet is a monolayer tablet, and wherein the tablet comprises about 5-30 mg copovidone, about 100-200 mg mannitol, about 50-100 mg microcrystalline cellulose, and about 5-10 mg magnesium stearate.

### Claim at position 12

31-40. (canceled)

### Claim 41 (depends on 19)

The tablet according to claim 19, wherein the tablet is coated with a film coating.

### Claim 42 (depends on 41)

The tablet according to claim 41, wherein the film coating comprises Opadry II or Opdary TF.

### Claim 43 (depends on 19)

The tablet according to claim 19, wherein the tablet comprises about 10-25% w/w bictegravir or a pharmaceutically acceptable salt thereof and about 5-25% w/w lenacapavir or a pharmaceutically acceptable salt thereof.

### Claim at position 16

44-46. (canceled)

### Claim 47 (depends on 19)

The tablet according to claim 19, wherein the tablet is a monolayer tablet, wherein the amount of bictegravir or pharmaceutically acceptable salt thereof corresponds to about 75 mg bictegravir free acid, and the amount of lenacapavir or pharmaceutically acceptable salt thereof corresponds to about 50 mg lenacapavir free acid, and wherein the tablet further comprises copovidone, poloxamer, mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

### Claim 48 (depends on 47)

The tablet according to claim 47, wherein the tablet is a monolayer tablet, wherein the amount of bictegravir or pharmaceutically acceptable salt thereof corresponds to about 75 mg bictegravir free acid, and the amount of lenacapavir or pharmaceutically acceptable salt thereof corresponds to about 50 mg lenacapavir free acid, and wherein the tablet comprises about 10-15 mg copovidone, about 2-5 mg poloxamer, about 150-175 mg mannitol, about 75-90 mg microcrystalline cellulose, about 30-40 mg croscarmellose sodium, and about 5-8 mg magnesium stearate.

### Claim 49 (depends on 48)

The tablet according to claim 48, wherein the tablet weighs about 410-460 mg.

### Claim at position 20

50-56. (canceled)

### Claim 57 (depends on 19)

The tablet according to claim 19, wherein the lenacapavir or pharmaceutically acceptable salt thereof is present in a spray dried dispersion.

### Claim at position 22

58-65. (canceled)

### Claim 66 (depends on 19)

A method of therapeutic treatment of an HIV infection comprising administering to a subject in need thereof a tablet according to claim 19.

### Claim 67 (depends on 19)

A method of preventing HIV infection comprising administering to a subject in need thereof a tablet according to claim 19.

### Claim 68

(canceled)

### Claim 69

(canceled)

### Claim 70 (depends on 66)

The method of claim 66, wherein the subject is virologically suppressed.

### Claim 71 (depends on 70)

The method according to claim 70, wherein the subject is treatment experienced.

### Claim at position 29

72-79. (canceled)

### Claim 80 (depends on 66)

The method according to claim 66, wherein the tablet is administered once daily.

### Claim 81 (depends on 80)

The method according to claim 80, wherein the tablet is administered once daily following a loading dose of lenacapavir or pharmaceutically acceptable salt thereof corresponding to about 1200 mg lenacapavir free acid.

### Claim 82 (depends on 81)

The method according to claim 81, wherein the loading dose is administered over two days.

### Claim 83 (depends on 82)

The method according to claim 82, wherein an amount of lenacapavir or pharmaceutically acceptable salt thereof corresponding to about 600 mg lenacapavir free acid is administered on the first day, and an amount of lenacapavir or pharmaceutically acceptable salt thereof corresponding to about 600 mg lenacapavir free acid is administered on the second day.

### Claim 84

A tablet comprising bictegravir or a pharmaceutically acceptable salt thereof and lenacapavir or a pharmaceutically acceptable salt thereof, wherein the amount of bictegravir or pharmaceutically acceptable salt thereof corresponds to about 75 mg bictegravir free acid, and wherein the amount of lenacapavir or pharmaceutically acceptable salt thereof corresponds to about 50 mg lenacapavir free acid wherein
the bictegravir or pharmaceutically acceptable salt thereof is bictegravir sodium and the lenacapavir or pharmaceutically acceptable salt thereof is lenacapavir sodium; and wherein
the tablet is a monolayer tablet.

### Claim 85 (depends on 84)

The tablet according to claim 84, wherein the tablet further comprises at least one excipient selected from: copovidone, poloxamer, mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

### Claim 86 (depends on 85)

The tablet according to claim 85, wherein the tablet comprises copovidone, poloxamer, mannitol, microcrystalline cellulose, croscarmellose sodium and magnesium stearate.

### Claim 87 (depends on 86)

The tablet according to claim 86, wherein the tablet comprises about 5-50 mg copovidone, about 0.5-10 mg poloxamer, about 50-200 mg mannitol, about 50-250 mg microcrystalline cellulose, about 25-50 mg croscarmellose sodium and about 1-10 mg magnesium stearate.

### Claim 88 (depends on 87)

The tablet according to claim 87, wherein the tablet is a monolayer tablet, and wherein the tablet comprises about 5-30 mg copovidone, about 100-200 mg mannitol, about 50-100 mg microcrystalline cellulose, and about 5-10 mg magnesium stearate.

### Claim 89 (depends on 84)

A method of therapeutic treatment of an HIV infection comprising administering to a subject in need thereof a tablet according to claim 84.

### Claim 90 (depends on 84)

A method of preventing HIV infection comprising administering to a subject in need thereof a tablet according to claim 84.

### Claim 91 (depends on 89)

The method according to claim 89, wherein the tablet is administered once daily.
